At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
INCB054707 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating INCB054707 and Placebo for Hidradenitis Suppurativa. Completed, enrolled 35 participants across 13 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesCanada, Denmark, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartOct 2018
Primary CompletionAug 2019
TodayJul 2026
First PostedJul 31, 2018
Enrollment StartOct 15, 2018
Primary CompletionAug 13, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.9 years ago
Interventions
INCB054707drug
INCB054707 tablet administered orally once daily at the protocol-defined dose.
Placebodrug
Placebo tablet administered orally once daily.